BD interim CFO granted 931 BDX shares

Becton Dickinson & Co. interim CFO Vitor Roque reported receiving a grant of 931 shares of common stock on March 2, 2026, at a stated price of $0.00 per share as a stock award.

Accepted by SEC EDGAR 03/04/2026 - 11:47 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Becton Dickinson & Co. interim CFO Vitor Roque reported receiving a grant of 931 shares of common stock on March 2, 2026, at a stated price of $0.00 per share as a stock award. After this acquisition, his directly held stake increased to 6,510 common shares. A footnote explains that his direct holdings reflect adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

Insider Trade Summary

Grant/Award: 931 shares

Grant/Award 1 txn

Insider Roque Vitor

Role Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	931	$0.00	$0.00

Holdings After Transaction: Common Stock — 6,510 shares (Direct)

Holdings Before and After: Common Stock, 5,579 to 6,510 shares (Direct)

Footnotes (1)

1. F1. Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Becton Dickinson (BDX) report for Vitor Roque?

Becton Dickinson reported that interim CFO Vitor Roque received a grant of 931 shares of common stock on March 2, 2026. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open‑market purchase.

How many Becton Dickinson (BDX) shares does Vitor Roque hold after this Form 4?

After the reported grant, interim CFO Vitor Roque directly holds 6,510 shares of Becton Dickinson common stock. This total includes the newly acquired 931-share award and reflects adjustments described in a footnote related to the Waters Corp. business combination.

Was Vitor Roque’s Becton Dickinson (BDX) share grant an open‑market purchase?

No, the filing classifies the March 2, 2026 transaction as a grant, award, or other acquisition of 931 common shares at a price of $0.00 per share. This indicates stock-based compensation, not an open‑market buy on a stock exchange.

What does the Form 4 footnote say about Vitor Roque’s Becton Dickinson (BDX) holdings?

The footnote states that Roque’s direct holdings reflect adjustments connected to combining the Biosciences and Diagnostic Solutions businesses with Waters Corp. It explains that these adjustments affected the number of shares underlying previously reported, unvested time‑vested restricted stock units.

What role does Vitor Roque hold at Becton Dickinson (BDX) in this Form 4?

In this Form 4, Vitor Roque is identified as the interim chief financial officer of Becton Dickinson. His reported transaction involves a stock award of 931 common shares, classified as a grant or other acquisition rather than a purchase or sale in the market.

Does the Becton Dickinson (BDX) Form 4 show any insider share sales by Vitor Roque?

No, the summarized Form 4 shows only an acquisition transaction for Vitor Roque, involving a grant of 931 common shares. There are no reported sales or dispositions in this excerpt, and his total direct ownership increases to 6,510 shares after the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roque Vitor

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		931	A	$0	6,510(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Remarks:

	Donna Kalazdy, by Power of Attorney from Vitor Roque	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.